Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...
Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...
Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management ...
Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...
In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...
The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results